Breast cancer adjuvant therapy

NIH Consensus Conference, scheduled for Sept. 9-11 at institutes' Masur Auditorium. Consensus statement will address five questions: "Have adjuvant chemotherapy trials in breast cancer demonstrated an increase in survival in any group of patients?" * * "What are the significant adverse effects of adjuvant therapy?" I I"What is the role of endocrine treatment in adjuvant therapy of breast cancer?" * * "When should women with histologically negative axillary lymph nodes receive adjuvant therapy?" * * "What directions for future research are indicated?" Contact Peter Murphy: [phone]. . . .